Mohammad Alashqar/LinkedIn
May 20, 2026, 12:42
Mohammad Alashqar: Cost-Effectiveness of Fitusiran Prophylaxis in Severe Hemophilia A Without Inhibitors
Mohammad Alashqar, Postdoctoral Pharmacotherapy Research Fellow at The Ohio State University College of Pharmacy, shared on LinkedIn:
”Proud to present poster N 3044 at ISPOR – The Professional Society for Health Economics and Outcomes Research 2026 on the ‘cost-effectiveness of fitusiran prophylaxis versus FVIII prophylaxis or on-demand therapy for patients with severe hemophilia A without inhibitors.’
Grateful to represent The Ohio State University College of Pharmacy and contribute to discussions advancing HEOR, value assessment, and evidence-based care.”
Stay updated with Hemostasis Today.
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association
-
Jul 2, 2026, 16:22Shinto Francis Thekkudan: Delegates Visiting our BMT and Hematology Department from Kazhakstan
-
Jul 2, 2026, 16:13William Aird: When Deciding whether an Adult Patient is Anemic, Which Do You Usually Use?
-
Jul 2, 2026, 16:08Supporting Bleeding Disorders Community and Celebrating ASPEH Milestone – WFH
-
Jul 2, 2026, 15:59Raul Santos: Why Does LDL-C Remain Elevated in Many Patients?
-
Jul 2, 2026, 15:16Tim Patel: How Regular Movement Helps Keep Blood Flowing Throughout the Day